ML-60218 is otherwise effective at inhibiting Pol III transcription in contexts with high POLR3G expression, including breast and prostate cancer cell lines (Nabet et al., 2017; Petrie et al., 2019). The gene discussed is POLR3G; the disease is prostate carcinoma.